In Vitro Immunological Effects of Blocking CCR5 on T Cells

Inflammation

Volumn 38, Issue 2, 2015, Pages 902-910

  Yuan, Jing ^a   Ren, Han yun ^a   Shi, Yong jin ^a   Liu, Wei ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

blocking CCR5; chemotaxis; cross talk; T cell activation

Indexed keywords

BETA ACTIN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MARAVIROC; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST;

APOPTOSIS; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; INTERNALIZATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; NEUTROPHIL CHEMOTAXIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; CELL CULTURE; DRUG EFFECTS; IMMUNOLOGY; MONONUCLEAR CELL; T LYMPHOCYTE;

CCR5 RECEPTOR ANTAGONISTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, CCR5; T-LYMPHOCYTES;

EID: 84925511560     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0052-6     Document Type: Article

References (23)

1. Lederman, M.M., A. Penn-Nicholson, M. Cho, and D. Mosier. 2006. Biology of CCR5 and its role in HIV infection and treatment. JAMA 296(7): 815–26.
2. Alkhatib, G. 2009. The biology of CCR5 and CXCR4. Current Opinion in HIV and AIDS 4(2): 96–103.
3. Geleff, S., D. Draganovici, P. Jaksch, and S. Segerer. 2010. The role of chemokine receptors in acute lung allograft rejection. The European Respiratory Journal 35(1): 167–75.
4. Lo, D.J., T.A. Weaver, D.E. Kleiner, R.B. Mannon, L.M. Jacobson, B.N. Becker, et al. 2011. Chemokines and their receptors in human renal allotransplantation. Transplantation 91(1): 70–7.
5. Palmer, L.A., G.E. Sale, J.I. Balogun, D. Li, D. Jones, J.J. Molldrem, et al. 2010. Chemokine receptor CCR5 mediates allo-immune responses in graft-versus-host disease. Biology of Blood and Marrow Transplantation 16(3): 311–9.
6. Ukena, S.N., S. Velaga, R. Geffers, J. Grosse, U. Baron, S. Buchholz, et al. 2011. Human regulatory T cells in allogeneic stem cell transplantation. Blood 118(13): e82–92.
7. Wysocki, C.A., S.B. Burkett, A. Panoskaltsis-Mortari, S.L. Kirby, A.D. Luster, K. McKinnon, et al. 2004. Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. The Journal of Immunology 173(2): 845–54.
8. Murai, M., H. Yoneyama, T. Ezaki, M. Suematsu, Y. Terashima, A. Harada, et al. 2003. Peyer’s patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nature Immunology 4(2): 154–60.
9. Hütter, G., M. Neumann, D. Nowak, S. Klein, H. Klüter, and W.K. Hofmann. 2011. The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation. The Journal of Inflammation (London) 8: 29.
10. Gilliam, B.L., D.J. Riedel, and R.R. Redfield. 2011. Clinical use of CCR5 inhibitors in HIV and beyond. Journal of Translational Medicine 9(1): S9.
11. Qiao, S., H. Ren, Y. Shi, and W. Liu. 2014. Allogeneic compact bone-derived mesenchymal stem cell transplantation increases survival of mice exposed to lethal total body irradiation: a potential immunological mechanism. Chinese Medical Journal 127(3): 475–82.
12. Gulick, R.M., J. Lalezari, J. Goodrich, N. Clumeck, E. DeJesus, A. Horban, et al. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. The New England Journal of Medicine 359(14): 1429–41.
13. Boesecke, C., and S.L. Pett. 2012. Clinical studies with chemokine receptor-5 (CCR5)-inhibitors. Current Opinion in HIV and AIDS 7(5): 456–62.
14. Tan, Q., Y. Zhu, J. Li, Z. Chen, G.W. Han, I. Kufareva, et al. 2013. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341(6152): 1387–90.
15. Arberas, H., and A.C. Guardo. 2013. Bargallo’ ME, Maleno MJ, Calvo M, Blanco JL, et al. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. The Journal of Antimicrobial Chemotherapy 68(3): 577–86.
16. Rossi, R., M. Lichtner, A. De Rosa, I. Sauzullo, F. Mengoni, A.P. Massetti, et al. 2011. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clinical and Experimental Immunology 166(2): 184–90.
17. Reshef, R., S.M. Luger, E.O. Hexner, A.W. Loren, N.V. Frey, S.D. Nasta, et al. 2012. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. The New England Journal of Medicine 367(2): 135–45.
18. Pulido, I., K. Machmach, M.C. Romero-Sanchez, M. Genebat, G. Mendez-Lagares, E. Ruiz-Mateos, et al. 2012. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity. The Journal of Infection 64(4): 417–23.
19. Funderburg, N., M. Kalinowska, J. Eason, J. Goodrich, J. Heera, H. Mayer, et al. 2010. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS ONE 5(10): e13188.
20. Choi, S.W., G.C. Hildebrandt, K.M. Olkiewicz, D.A. Hanauer, M.N. Chaudhary, I.A. Silva, et al. 2007. CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood 110(9): 3447–55.
21. O’Boyle, G., J.G. Brain, J.A. Kirby, and S. Ali. 2007. Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2. Molecular Immunology 44(8): 1944–53.
22. El-Asmar, L., J.Y. Springael, S. Ballet, E.U. Andrieu, G. Vassart, and M. Parmentier. 2005. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Molecular Pharmacology 67(2): 460–9.
23. Salanga, C.L., M. O’Hayre, and T. Handel. 2009. Modulation of chemokine receptor activity through dimerization and crosstalk. Cellular and Molecular Life Sciences 66(8): 1370–86.